SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • December 18th, 2009 • Raptor Pharmaceutical Corp • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of December 17, 2009 between Raptor Pharmaceutical Corp., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and permitted assigns, a “Purchaser” and collectively the “Purchasers”).
3,747,558 Shares of Common Stock and Warrants to Purchase 3,747,558 Shares of Common Stock RAPTOR PHARMACEUTICAL CORP. PLACEMENT AGENT AGREEMENTPlacement Agent Agreement • December 18th, 2009 • Raptor Pharmaceutical Corp • Pharmaceutical preparations • New York
Raptor Pharmaceutical Corp., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions of this Placement Agent Agreement (this “Agreement”) and the Securities Purchase Agreement in the form of Exhibit A attached hereto (the “Purchase Agreement”) to be entered into with certain investors identified therein (each, an “Investor,” and collectively, the “Investors”), in connection with the proposed placement (the “Placement”) to issue and sell to the Investors (i) up to an aggregate of 3,747,558 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”), (ii) warrants in the form attached hereto as Exhibit B (the “Series A Warrants”) to purchase shares of Common Stock and (iii) warrants in the form attached hereto as Exhibit C (the “Series B Warrants,” and collectively with the Series A Warrants, the “Warrants”) to purchase shares of Common Stock, in units (each, a “Unit”), each Unit consisting of (x) one share of Common
